Press Releases

Topics:
  TITLE DATE  
 
 

Teleconference Call of May 10, 2017

2017-05-11

 
 
Topic:  Other Topics
 
 

Recording of teleconference call of May 10, 2017.

 
 
 

NYMOX Files For Approval of First In Class Prostate Drug in Europe: Teleconference at 4:30 EDT

2017-05-10

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation will hold a teleconference call for shareholders today May 10 at 4:30 EDT. The call in number is 1-888-424-8151 and the passcode is 7826703# (for Canada please use 1-888-465-5079).

 
 
 

NYMOX Files For Approval of First In Class Prostate Drug in Europe: Company To Hold Teleconference Wednesday May 10 at 4:30 EDT

2017-05-08

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Following Nymox's announcement of the Company's filing for marketing approval of Fexapotide Triflutate for enlarged prostate (BPH) in Europe, Nymox is pleased to announce a teleconference with shareholders at 4:30 p.m. EST on Wednesday May 10, 2017.

 
 
 

Nymox Files For Marketing Approval For Fexapotide Triflutate in Europe

2017-05-03

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce today that the Company has filed to seek approval for marketing authorization for Fexapotide Triflutate in five European countries, comprising the Netherlands, the UK, Germany, France and Spain.

 
 
 

Nymox Provides Update on Fexapotide Development

2017-03-29

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation provided an update today on the Company's development activities for Fexapotide Triflutate, its new drug for prostate enlargement.

 
 
 

Nymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy

2016-11-29

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce that new Phase 3 prospective randomized clinical trial results have confirmed that patients who received fexapotide as their initial treatment for BPH (prostate enlargement) had superior efficacy results as early as 10 days compared to control patients who received placebo or who had prior history of other BPH medical treatments.

 
 
 

Nymox Reports Successful New Phase 3 Long-Term Fexapotide Repeat Injection BPH Trial Results: Lasting Symptomatic Improvement Up To 6 Years After Single Repeated Treatment

2016-10-11

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term repeated injection group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.

 
 
 

Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

2016-08-29

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation lead drug fexapotide which has been in development for over a decade and which has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers...

 
 
 

Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery

2016-08-24

 
 
Topic:  R&D: BPH (enlarged prostate) Treatments
 
 

Nymox Pharmaceutical Corporation is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer.

 
 
 

Nymox Announces Private Placements of $2.24 Million

2016-08-17

 
 
Topic:  Financial
 
 

Nymox Pharmaceutical Corporation is pleased to announce that it has recently closed private placements and other investments in the Company for a total of $2.24 million.

 
  Total   372   Records   First   Previous   1 of 38   Next   Last      Go